Infection Control Today

FEB 2019

ICT delivers to infection preventionists & their colleagues in the operating room, sterile processing/central sterile, environmental services & materials management, timely & relevant news, trends & information impacting the profession & the industry

Issue link: http://digital.infectioncontroltoday.com/i/1072566

Contents of this Issue

Navigation

Page 39 of 44

1. Proven in vitro to significantly (p=0.0133) inhibit bacterial attachment and biofilm formation † as compared with a commonly used polyurethane catheter*. 2. The POWERWAND is proven in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein. Based on canine jugular vein thromboresistance study, correlations to clinical applications has not been ascertained. † Based on laboratory test results which may not be indicative of clinical results. Data on file and refer to publication 3 . Preclinical in-vitro evaluations do not necessarily predict clinical performance with respect to catheter-related bloodstream infection. 3. Pathak R, Bierman S, d'Arnaud P. Inhibition of bacterial attachment and biofilm formation by a novel intravenous catheter material using an in vitro percutaneous catheter insertion model. Medical Devices: Evidence and Research. 2018;11:1-6. https://doi.org/10.2147/MDER.S183409. * PowerGlide ® (CR Bard, Salt Lake City, UT) - a registered trademark of C.R. Bard. BioGUARD™ and POWERWAND™ are trademarks of Access Scientific, LLC. ChronoFlex C ® is a registered trademark of AdvanSource Biomaterials Corp. LC-0576 Rev. B www.accessscientific.com ChronoFlex C ® with BioGUARD TM Technology First and only catheter proven to Inhibit Bacterial Attachment (in vitro) 1 & Resist Thrombus Formation (in vivo) 2 Where it Matters Most Infection Prevention By Design

Articles in this issue

Links on this page

Archives of this issue

view archives of Infection Control Today - FEB 2019